Two or more comorbidities affected nearly half of the ankylosing spondylitis (AS) patients in a large study of the disease, with the most common coexisting conditions being uveitis (eye inflammation), depression, and hypertension (high blood pressure). Those with no comorbidities were younger and had shorter disease duration, the researchers reported,…
People with ankylosing spondylitis (AS) who report more severe pain and disease activity, and poorer quality of life, continue to work despite their AS — yet their productivity is far less than that of patients whose outcomes are not as severe. That’s according to a new analysis of data…
AVT05, Alvotech’s biosimilar candidate to treat ankylosing spondylitis (AS) and other chronic inflammatory diseases, showed a similar pharmacological profile to the reference medication Simponi (golimumab) in a clinical trial. The Phase 1 trial (NCT05632211) compared the safety, tolerability, and pharmacokinetics — movement into, through, and out…
Uveitis, a form of eye inflammation, and lower socioeconomic status are both linked to a longer time to diagnosis in people with axial spondyloarthritis, known as axSpA, a study reports. In contrast, older age at symptom onset is associated with shorter delays, the researchers noted. “These results suggest that…
A man with ankylosing spondylitis (AS) went into disease remission within three months of receiving BCD-180, an experimental antibody designed to deplete a type of immune cell called TRBV9-positive T-cells, a study reports. He also stopped treatment with the TNF inhibitors he had taken continuously for five years,…
Up to five years of treatment with bimekizumab safely leads to sustained reductions in symptoms and disease activity, as well as improvements in physical function and life quality, for people with ankylosing spondylitis (AS). That’s according to new data from the now-completed Phase 2b BE AGILE clinical…
A year of treatment with bimekizumab was safe and significantly eased symptoms of axial spondyloarthritis (axSpA) in participants from two Phase 3 clinical trials, data show. “Results at [one year] from the BE MOBILE trials suggest that [bimekizumab] is an effective treatment option resulting in sustained efficacy across…
Note: This story was updated Oct. 31, 2023, to clarify that opioid use correlates with, rather than causes, an increased risk of bone fractures. People with ankylosing spondylitis (AS) who are taking opioids — to relieve pain or for other reasons — are up to almost twice as likely…
Children with one or more older siblings are up to 34% as likely as those who don’t have older siblings to develop ankylosing spondylitis (AS), a large Swedish study found. Having a tonsillectomy, a surgery to remove the tonsils when they repeatedly become infected before age 16, increased the…
People with ankylosing spondylitis (AS) who carry a mutation in the gene that encodes the CARD9 protein may be more likely to respond to treatments that block an inflammatory signaling molecule known as interleukin-17 (IL-17), a preclinical study suggests. Scientists found that the protein CARD9 is involved in…
Get regular updates to your inbox.